Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics), formerly Synthetic Blood International, Inc., is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. The Company is developing Oxycyte, an oxygen carrier for use in surgical and similar medical situations. Oxygen Biotherapeutics has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, it also has under development Fluorovent, an oxygen exchange fluid for facilitating the treatment of lung conditions, and out licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. In April 2009, the Company filed an application with the Food and Drug Administration of United States (FDA) to obtain orphan drug designation for Oxycyte for the treatment of patients with severe, closed-head traumatic brain injury (TBI).